Attovia Therapeutics, Inc. (ATTO) reports that President and CEO and director Tao Fu acquired a stock option award covering 538,300 shares of common stock on August 4, 2026. The options have a $17.00 exercise price and expire August 3, 2036. The amendment replaces the Form 4 submitted August 6, 2026, and states that no changes are being reported to Fu’s beneficial ownership.
Attovia Therapeutics, Inc. Chief Financial Officer Steven Chan was granted stock options on August 4, 2026, covering 140,000 common shares at an exercise price of $17 per share. Twenty-five percent vests on August 4, 2027; the remainder vests in equal monthly installments over the following 36 months, subject to continued service through those dates. The options expire August 3, 2036. The amendment replaces the August 6, 2026 Form 4 in its entirety and reports no changes to Chan’s beneficial ownership.
Attovia Therapeutics, Inc. amended Tao Fu’s Form 3, identifying him as President and CEO and a director, and states that no beneficial-ownership changes are reported. As of August 4, 2026, Fu directly held 87,843 common shares and held three direct stock-option positions covering 23,437 shares at $1.5793, 409,709 shares at $3.5302, and 370,290 shares at $4.9237. The options expire August 16, 2033, May 8, 2034, and May 17, 2035, respectively. The filing also lists common stock held through the TF 2025 Annuity Trust, TF 2026 Annuity Trust, and Hai Fu Revocable Trust.
Attovia Therapeutics, Inc. (ATTO) amended and replaced Steven Chan’s Form 3 filed August 4, 2026, reporting no change to his beneficial ownership. Chan, the Chief Financial Officer, directly holds options for 215,285 common shares at $3.5302, expiring November 13, 2034, and 80,731 shares at $4.9237, expiring May 17, 2035. For the first and second options, respectively, 25% of the underlying shares vested on October 14, 2025, and May 18, 2026; each provides for an additional 1/48th to vest monthly over three years, subject to continued service.
Attovia Therapeutics, Inc. (ATTO) reported unaudited results for the quarter and six months ended June 30, 2026, reflecting continued investment in its immune‑mediated disease pipeline and preparations for becoming a public company. For the first half of 2026, revenue was $0.45 million from a collaboration with EndPath, while operating expenses rose to $42.2 million, driven by $35.7 million of research and development spending and $6.5 million of general and administrative costs.
This produced a first‑half net loss of $39.3 million, compared with $29.6 million a year earlier, and an accumulated deficit of $150.4 million as of June 30, 2026. Cash, cash equivalents and marketable securities totaled $115.1 million at quarter‑end. Subsequent to the period, Attovia completed an IPO raising approximately $305.4 million in net proceeds and effected a 1‑for‑9.29 reverse stock split, with all share and per‑share data retrospectively adjusted. Management states that existing cash, cash equivalents and marketable securities together with IPO proceeds are expected to fund planned operations into 2030.
Attovia Therapeutics, Inc. (ATTO) reported second quarter 2026 results and a corporate update, highlighted by preliminary clinical proof of concept for lead candidate ATTO-1310 in chronic pruritus and high-itch atopic dermatitis, showing rapid, deep itch relief and lesion control in a Phase 1b study.
The company plans two global Phase 2 trials of ATTO-1310 in chronic pruritus of unknown origin and high-itch atopic dermatitis, both targeted to start in the first half of 2027, and is advancing ATTO-2306 and ATTO-1091 toward Phase 1 initiation in the same timeframe. Early program ATTO-006 is being moved toward development candidate nomination by year-end 2026.
Attovia completed an upsized IPO with $332.4 million in gross proceeds and expects that existing cash, cash equivalents and marketable securities, including $305.4 million of IPO net proceeds, will fund operations into 2030. For the quarter ended June 30, 2026, collaboration revenue was $0.5 million, research and development expenses were $18.9 million, and net loss was $20.7 million. Cash, cash equivalents and marketable securities were $115.1 million as of June 30, 2026, prior to the August IPO.
Attovia Therapeutics, Inc. (ATTO) is the issuer in a Notice of Proposed Sale of Securities on Form 144 filed in connection with planned sales of its common stock by Goldman Sachs Group Inc., identified as a former 10% owner. The notice covers up to 105,807 shares of Attovia common stock. The shares to be sold were acquired through securities borrowing by Goldman Sachs & Co. LLC, which is acting as a market maker in the ordinary course of business, and trades may occur on CBOE, IEX, MEMX and Nasdaq. The Form 144 is a resale notice for the selling party; Attovia does not sell shares or receive proceeds in this transaction.
Attovia Therapeutics, Inc. (ATTO) is the subject of an amended Form 4 reporting complex indirect transactions associated with director Colin Walsh and entities affiliated with The Goldman Sachs Group Inc. Series B and C Preferred Stock automatically converted into common stock at a 9.29-for-1 ratio upon the IPO closing on August 6, 2026, eliminating those preferred holdings. Goldman Sachs & Co. LLC, acting as a market maker, reported purchases and sales of common stock and the establishment of long equity swap positions, with any profit potentially recoverable under Section 16(b) to be remitted to Attovia. The amendment also corrects an earlier administrative error in the number of common shares issuable upon conversion, and Walsh disclaims beneficial ownership except to the extent of any pecuniary interest.
Attovia Therapeutics, Inc. (ATTO) reported insider activity by multiple Goldman Sachs–affiliated entities, all listed as former 10% owners. On August 6, 2026, they reported the conversion of Series B and Series C Preferred Stock into common stock, eliminating 18,181,830 Series B and 4,445,275 Series C preferred shares and issuing 1,957,134 and 478,598 common shares, respectively. This corrects an administrative error in an earlier Form 3 and reflects automatic conversion upon the IPO after a 1‑for‑9.29 reverse stock split.
On the same date, an affiliated entity purchased 500,000 common shares at $17.00 per share. On August 5, 2026, Goldman Sachs & Co. LLC, acting as a market maker, purchased 85,000 shares, sold 105,807 shares, and entered into long equity swap positions referencing 105,807 shares at prices around $21.22–$21.27. The reporting persons disclaim beneficial ownership except to the extent of any pecuniary interest, and any Section 16(b) profit from the market‑making trades will be remitted to Attovia.
Attovia Therapeutics, Inc. director Colin Walsh, affiliated with Goldman Sachs entities, reported the automatic conversion of 22,627,105 shares of Series B and C Preferred Stock into common stock on a 9.29-for-1 basis upon the company’s IPO closing on August 6, 2026, with no cash consideration. The resulting common shares are held indirectly through multiple Goldman Sachs-managed investment vehicles, and Walsh disclaims beneficial ownership beyond any pecuniary interest. On August 5–6, 2026, Goldman Sachs & Co. LLC, acting as a market maker, purchased 585,000 ATTO common shares (including 500,000 at $17.00 and 85,000 at $21.00) and sold 105,807 shares around $21–22 per share; any profit recoverable under Section 16(b) will be remitted to Attovia.